StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID Media Coverage, News […] StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID more →
StemCyte Introduces Insurance-Linked Cord Blood Access in Taiwan Media Coverage, News StemCyte Introduces Insurance-Linked Cord Blood Access in Taiwan more →
StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection Media Coverage, News StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection more →
StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms Media Coverage, News StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms more →
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product Media Coverage, News U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product more →
StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment Media Coverage, News StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment more →
StemCyte Renews Contract with the California State Umbilical Cord Blood Collection Program Media Coverage StemCyte Renews Contract with the California State Umbilical Cord Blood Collection Program more →
Interview with StemCyte CEO Tong-Young Lee PhD News, Media Coverage Interview with StemCyte CEO Tong-Young Lee PhD more →
StemCyte signs a cooperation agreement with a cutting-edge US immune cell therapy company to supply drug preparation raw materials for allogeneic modified cell therapy Media Coverage StemCyte signs a cooperation agreement with a cutting-edge US immune cell therapy company to supply drug preparation raw materials for allogeneic modified cell therapy more →
The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients. Media Coverage The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients. more →
